Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DRD2 | P14416 | 11/20 | 0.63 |
| ▸ | DRD3 | P35462 | 9/20 | 0.63 |
| ▸ | CACNA1G | O43497 | 2/20 | 0.53 |
| ▸ | MTNR1A | P48039 | 1/20 | 0.52 |
| ▸ | MTNR1B | P49286 | 1/20 | 0.52 |
| ▸ | HTR1A | P08908 | 5/20 | 0.52 |
| ▸ | DRD4 | P21917 | 3/20 | 0.52 |
| ▸ | HTR2B | P41595 | 3/20 | 0.52 |
| ▸ | HTR2A | P28223 | 5/20 | 0.51 |
| ▸ | HTR2C | P28335 | 2/20 | 0.51 |
| ▸ | DRD1 | P21728 | 1/20 | 0.51 |
| ▸ | TP53 | P04637 | 1/20 | 0.49 |
| ▸ | MAPT | P10636 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4478529 | 1.00 | DRD2 (0.63) | DRD2DRD3CACNA1GMTNR1AMTNR1B | |
| SCHEMBL13630265 | 0.95 | DRD2 (0.65) | DRD2DRD3CACNA1GMTNR1AMTNR1B | |
| SCHEMBL4492292 | 0.95 | DRD2 (0.65) | DRD2DRD3CACNA1GMTNR1AMTNR1B | |
| SCHEMBL4482724 | 0.92 | DRD2 (0.54) | DRD2DRD3HTR1ADRD4HTR2B | |
| SCHEMBL13630235 | 0.92 | DRD2 (0.54) | DRD2DRD3HTR1ADRD4HTR2B | |
| SCHEMBL4495114 | 0.92 | DRD2 (0.53) | DRD2DRD3HTR1ADRD4HTR2B | |
| SCHEMBL13630412 | 0.92 | DRD2 (0.53) | DRD2DRD3HTR1ADRD4HTR2B | |
| SCHEMBL4494995 | 0.90 | DRD2 (0.60) | DRD2DRD3HTR1ADRD4HTR2B | |
| SCHEMBL13630473 | 0.90 | DRD2 (0.60) | DRD2DRD3HTR1ADRD4HTR2B | |
| SCHEMBL13630051 | 0.90 | CHRM4 (0.57) | DRD2DRD3HTR1ADRD4HTR2B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090286801-A1 | CARBONYLATED (AZA) CYCLOHEXANES AS DOPAMINE D3 RECEPTOR LIGANDS | BIOPROJET (FR) | 2009-11-19 | — | — | US | disclosed |
| US-20090286801-A1 | CARBONYLATED (AZA) CYCLOHEXANES AS DOPAMINE D3 RECEPTOR LIGANDS | BIOPROJET (FR) | 2009-11-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090286801-A1 | CARBONYLATED (AZA) CYCLOHEXANES AS DOPAMINE D3 RECEPTOR LIGANDS | DRD3, TACR2, TACR1 | DRD2 4/4885DRD3 1/4885CACNA1G 2326/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.